Cellectis SANASDAQ:CLLS
- LAST PRICE1.8503
- TODAY'S CHANGE (%)-0.0797 (-4.1295%)
- Bid / Lots1.8500/ 1
- Ask / Lots1.8700/ 9
- Open / Previous Close1.8600 / 1.9300
- Day Range
- 52 Week Range
- Volume80,487
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CLLS |
|---|---|---|
| 09:32 ET | 12799 | 1.86 |
| 09:39 ET | 7600 | 1.85 |
| 09:48 ET | 130 | 1.87 |
| 09:50 ET | 414 | 1.8601 |
| 09:52 ET | 180 | 1.855 |
| 09:54 ET | 150 | 1.86 |
| 09:56 ET | 293 | 1.86 |
| 10:01 ET | 1900 | 1.85 |
| 10:03 ET | 2590 | 1.85 |
| 10:06 ET | 300 | 1.8501 |
| 10:32 ET | 2000 | 1.852 |
| 10:37 ET | 160 | 1.85 |
| 11:00 ET | 3900 | 1.85 |
| 11:02 ET | 9970 | 1.85 |
| 11:09 ET | 6800 | 1.86 |
| 11:11 ET | 8500 | 1.8699 |
| 11:15 ET | 9180 | 1.85 |
| 12:43 ET | 1085 | 1.83 |
| 12:45 ET | 400 | 1.82 |
| 12:52 ET | 100 | 1.86 |
| 01:03 ET | 100 | 1.8402 |
| 01:06 ET | 240 | 1.85 |
| 01:39 ET | 100 | 1.85 |
| 02:24 ET | 300 | 1.84 |
| 02:29 ET | 234 | 1.8503 |
Jun 20, 2024
Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing, from 4:30PM ET on Thursday Jun 20, 2024 by Dow Jones
4:30PM ET on Thursday Jun 20, 2024 by Dow Jones
Jun 12, 2024
Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications, from 4:30PM ET on Wednesday Jun 12, 2024 by Dow Jones
4:30PM ET on Wednesday Jun 12, 2024 by Dow JonesDJ Cellectis Is Maintained at Outperform by Oppenheimer, from 9:37AM ET on Wednesday Jun 12, 2024 by Dow Jones
9:37AM ET on Wednesday Jun 12, 2024 by Dow Jones
Jun 4, 2024
Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia, from 4:30PM ET on Tuesday Jun 04, 2024 by Dow Jones
4:30PM ET on Tuesday Jun 04, 2024 by Dow Jones
May 31, 2024
DJ Cellectis Price Target Maintained With a $6.00/Share by JMP Securities, from 11:38AM ET on Friday May 31, 2024 by Dow Jones
11:38AM ET on Friday May 31, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cellectis SA | 133.1M | -1.0x | --- |
Capricor Therapeutics Inc | 147.6M | -5.2x | --- |
Elutia Inc | 92.5M | -1.6x | --- |
Mediwound Ltd | 135.5M | -10.7x | --- |
Adagene Inc | 125.0M | -6.8x | --- |
Fennec Pharmaceuticals Inc | 169.4M | 165.2x | --- |
Company Information
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
Contact Information
- Headquarters
- 8, rue de la Croix JarryPARIS, France 75013
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- Jean-Pierre Garnier
- Chief Executive Officer, Co-Founder, Director
- Andre Choulika
- Deputy Chief Executive Officer, Co-Founder, Executive Vice President - CMC and Manufacturing, Director
- David Sourdive
- Interim Chief Financial Officer
- Arthur Stril
- Chief Human Resource Officer, Executive Vice President
- Kyung Nam-Wortman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $133.1M |
|---|---|
Revenue (TTM) | $25.5M |
Shares Outstanding | 72.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 3.10 |
EPS | $-1.93 |
Book Value | $2.58 |
P/E Ratio | -1.0x |
Price/Sales (TTM) | 5.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -329.10% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
